Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Howland E. Crosswell"'
Autor:
Howland E. Crosswell, Ann S. LaCasce, Nancy L. Bartlett, David J. Straus, Kerry J. Savage, Pier Luigi Zinzani, Graham P. Collins, Michelle Fanale, Keenan Fenton, Cassie Dong, Harry Miao, Andrew P. Grigg
Publikováno v:
Haematologica, Vol 109, Iss 3 (2023)
Externí odkaz:
https://doaj.org/article/812cd0e47a2943868ab741041339d5d9
Autor:
William G. Blum, Arati V. Rao, Hubert Serve, Thomas Oellerich, Yang Pan, Jinfeng Liu, Lauren Long, Veerendra Munugalavadla, Mark D. Minden, Danjie Zhang, Howland E. Crosswell, Tara L. Lin, Shelley Orwick, Alice S. Mims, Bhavana Bhatnagar, James S. Blachly, John C. Byrd, Alison R. Walker
Suppl Figures 1-3, Suppl Table 1 Supplemental Figure 1. Study schema. Supplemental Figure 2. Overall survival in patients treated with ENTO + 7+3. OS is censored on the date the patient was last known to be alive (if it was not known the patient had
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::729ff97aaf1985b8f717f96ec31b7d7e
https://doi.org/10.1158/1078-0432.22476270
https://doi.org/10.1158/1078-0432.22476270
Autor:
William G. Blum, Arati V. Rao, Hubert Serve, Thomas Oellerich, Yang Pan, Jinfeng Liu, Lauren Long, Veerendra Munugalavadla, Mark D. Minden, Danjie Zhang, Howland E. Crosswell, Tara L. Lin, Shelley Orwick, Alice S. Mims, Bhavana Bhatnagar, James S. Blachly, John C. Byrd, Alison R. Walker
Purpose:Spleen tyrosine kinase (SYK) signaling is a proposed target in acute myeloid leukemia (AML). Sensitivity to SYK inhibition has been linked to HOXA9 and MEIS1 overexpression in preclinical studies. This trial evaluated the safety and efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68718286b612ecd09aa15987c54606bc
https://doi.org/10.1158/1078-0432.c.6529353
https://doi.org/10.1158/1078-0432.c.6529353
Autor:
Elizabeth J Siembida, Holli A Loomans-Kropp, Irene Tami-Maury, David R Freyer, Lillian Sung, Howland E Crosswell, Brad H Pollock, Michael E Roth
Publikováno v:
The oncologist, vol 27, iss 5
Background Adolescent and young adult (AYA) patients with cancer are underrepresented on cancer clinical trials (CCTs), and most AYAs are treated in the community setting. Past research has focused on individual academic institutions, but factors imp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddc0d0805ece623fdbefc98b76f4923d
https://escholarship.org/uc/item/72z3h2w3
https://escholarship.org/uc/item/72z3h2w3
Autor:
Bhavana Bhatnagar, Arati V. Rao, James S. Blachly, Tara L. Lin, Alison Walker, Howland E. Crosswell, William Blum, Jinfeng Liu, Veerendra Munugalavadla, Lauren Long, Danjie Zhang, Mark D. Minden, Yang Pan, Hubert Serve, John C. Byrd, Alice S. Mims, Thomas Oellerich, Shelley Orwick
Publikováno v:
Clinical Cancer Research. 26:5852-5859
Purpose: Spleen tyrosine kinase (SYK) signaling is a proposed target in acute myeloid leukemia (AML). Sensitivity to SYK inhibition has been linked to HOXA9 and MEIS1 overexpression in preclinical studies. This trial evaluated the safety and efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c2fec3766059d9b48d163577b0fe1fe
https://doi.org/10.1158/1078-0432.ccr-20-1064
https://doi.org/10.1158/1078-0432.ccr-20-1064
Autor:
Amy Adams, Alexandra Conry, Howland E. Crosswell, Robert D. Siegel, Alfred W Campbell, Daniel B Fried, James D. Bearden, Melissa Peters
Publikováno v:
Journal of Adolescent and Young Adult Oncology. 9:449-452
Alveolar soft part sarcoma (ASPS) is an extremely rare tumor that frequently occurs in adolescent and young adults (AYA). Survival is poor for patients with metastatic and/or relapsed disease not amenable to local control, and limited therapeutic opt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::966dda780df4d217013bdb56b35c476b
https://doi.org/10.1089/jayao.2019.0113
https://doi.org/10.1089/jayao.2019.0113
Autor:
Ann S. LaCasce, Nancy L. Bartlett, Kerry J. Savage, David J. Straus, Harry H. Miao, Andrew Grigg, Howland E. Crosswell, Pier Luigi Zinzani, Graham P. Collins, Keenan Fenton, Cassie Dong, Michelle A. Fanale
Publikováno v:
Hematological Oncology. 39
7528 Background: Hodgkin lymphoma (HL) is a rare disease that commonly occurs in adolescents and young adults (AYAs) which is typically defined as 15 to 39 years. Given their young age at presentation, key factors in treatment selection include a hig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e51682d16067f5e1370603b7e2debb8
https://doi.org/10.1002/hon.38_2879
https://doi.org/10.1002/hon.38_2879
Autor:
G. Larry Maxwell, Alpa M. Nick, Michael P. Stany, Christine Wilhelm, Stephen Shuford, Lauren O’Donnell, Howland E. Crosswell, Ashley M. Smith, Thomas P. Conrads, Melissa Millard, Xiaonan Hou, Larry Puls, Alina Lotstein, Valentina Zanfagnin, David E. Orr, S. John Weroha, Lillia Holmes, Jeffrey Elder, Teresa M. DesRochers, Ashley Elrod, Qi Jin Guo, Christina Mattingly, Melissa Rayner, Matthew R. Gevaert, Anil K. Sood
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-13 (2019)
Scientific Reports
Scientific Reports
Although 70–80% of newly diagnosed ovarian cancer patients respond to first-line therapy, almost all relapse and five-year survival remains below 50%. One strategy to increase five-year survival is prolonging time to relapse by improving first-line
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7f835166b75d5ddba7d80f8b15f0502
http://link.springer.com/article/10.1038/s41598-019-47578-7
http://link.springer.com/article/10.1038/s41598-019-47578-7
Autor:
Howland E. Crosswell, Erin B Hill, Kristina Stoeppler-Biege, Lara H Widener, Dionne Pringle, Robert D. Siegel, Theresa M Standifer, Terra F Spann, Michael Borron, Karen K Hancock, Richard Slough
Publikováno v:
Journal of Oncology Practice. 15:e628-e635
PURPOSE: The cost of cancer care is escalating dramatically, in part because of the rising expense of systemic cancer therapy. This creates financial dilemmas for patients and insurers and potential economic disruption for institutions attempting to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44073debe5008b0bbbdee965e8323bc4
https://doi.org/10.1200/jop.19.00016
https://doi.org/10.1200/jop.19.00016
Autor:
Howland E Crosswell, Holli A. Loomans-Kropp, David R. Freyer, Irene Tamí-Maury, Brad H. Pollock, Michael Roth, Lillian Sung, Elizabeth J. Siembida
Publikováno v:
JNCI cancer spectrum, vol 5, iss 3
JNCI Cancer Spectrum
JNCI Cancer Spectrum
Background Although it is well documented that adolescents and young adults (AYAs) with cancer have low participation in cancer clinical trials (CCTs), the underlying reasons are not well understood. We used the National Cancer Institute Community On
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5652414b62fcd60d4cab4cb963d0f992
https://pubmed.ncbi.nlm.nih.gov/34104866
https://pubmed.ncbi.nlm.nih.gov/34104866